Positive treatment response of pritelivir achieved in refractory HSV infections in immunocompromised patients, including haematopoietic stem cell and solid organ transplant recipients and oncology patients: PRIOH-1 phase III trial (ESCMID Global 2026) - Mar 6, 2026 - Abstract #L0016; Pres time: Apr 19, 2026; 11:00 AM - 11:12 AM; Location: Hall B0-2; No abstract available
Clinical • Late-breaking abstract • P3 data • Herpes Simplex • Infectious Disease • Solid Organ Transplantation • Transplantation
|
|
R. Chemaly; K. Peggs; D. Neofytos; K. Workowski; R. Avery; Y.J. Lee; R. Maves; O. Cornely; J. Stemler; D. Teschner; M. Yong; J. Sasadeusz; S. Dadwal; J. Dickter; A. Birkmann; C. Wat; D.C. Herath; A. Marini; B. Surujbally; M. Sumner; G.A. Papanicolaou
|